Affimed’s AFM13 Data Show Potential Of NK Cell Approach

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.

3d illustration of T cells attacking a cancer cell
Affimed announced interim data from its study of AF13 with pre-complexed NK cells • Source: Shutterstock

Interim data from an investigator-sponsored Phase I/II study of Affimed N.V.’s bispecific engager AFM13 combined with natural killer (NK) cells in CD30-positive lymphomas bring the company a step closer toward carving out a registration path for the product. The latest data build on prior results of the therapy in peripheral T-cell lymphoma and also in combination with Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab), but the new findings highlight the added benefit of the NK cell approach.

Affimed announced interim data on 22 November from 16 patients in the AFM13-104 trial who have CD30-positive relapsed or refractory...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

What To Look Out For At ESMO 2024

 
• By Alexandra Shimmings

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Anticancer

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Ordspono Will Be Regeneron’s First Independent European Launch

 
• By Jessica Merrill

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.